Merrimack Pharmaceuticals Other Liabilities

Merrimack Pharmaceuticals posts a other liabilities of $0 as of March 2024. That compares with $-89K in the prior-year period — up 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Merrimack Pharmaceuticals's other liabilities was $-89K. The latest reading is $0 — a 100.0% year-over-year increase (period ending March 2024). Use the history and growth charts on this page for a longer lookback.

Other Liabilities is one piece of Merrimack Pharmaceuticals's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MACK's other liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Merrimack Pharmaceuticals's other metric pages and overview cover the third.

Judging Merrimack Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other liabilities easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.